4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch

Human-cell tests can flag liver risks before clinical trials, VivoSim says.

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use

2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More

VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

In today's session, these stocks are experiencing unusual volume.

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth

VIVS Stock Whipsaws As Traders Target Volatile Moves

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting